AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.984
-0.056 (-5.35%)
Apr 28, 2026, 4:00 PM EDT - Market closed
AEON Biopharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -39.22 | 42.01 | -384.63 | -52.56 | -55.64 | |
| Depreciation & Amortization | 0.08 | 0.1 | 0.1 | 0.07 | 0 | |
| Other Amortization | - | - | - | 0.33 | 1.98 | |
| Asset Writedown & Restructuring Costs | - | - | 348 | - | - | |
| Stock-Based Compensation | 5.32 | 6.25 | 7 | 5.89 | 5.22 | |
| Other Operating Activities | 23.46 | -69.35 | -15.55 | 4.41 | 18.59 | |
| Change in Accounts Payable | -4.97 | 2.52 | -4.59 | 6.61 | -0.9 | |
| Change in Other Net Operating Assets | -1.97 | -1.82 | 1.85 | -0.35 | 2.31 | |
| Operating Cash Flow | -17.31 | -20.29 | -47.83 | -35.58 | -28.43 | |
| Capital Expenditures | -0 | - | - | -0.31 | -0.17 | |
| Investing Cash Flow | -0 | - | - | -0.31 | -0.17 | |
| Long-Term Debt Issued | - | 15 | 14 | 44.5 | 15 | |
| Long-Term Debt Repaid | - | - | - | -3.99 | - | |
| Total Debt Repaid | - | - | - | -3.99 | - | |
| Net Debt Issued (Repaid) | - | 15 | 14 | 40.51 | 15 | |
| Issuance of Common Stock | 18.51 | 0.15 | - | - | - | |
| Other Financing Activities | 1.79 | - | - | - | -1.44 | |
| Financing Cash Flow | 20.31 | 15.15 | 14 | 40.51 | 13.56 | |
| Net Cash Flow | 2.99 | -5.15 | -33.83 | 4.62 | -15.04 | |
| Free Cash Flow | -17.31 | -20.29 | -47.83 | -35.89 | -28.6 | |
| Free Cash Flow Per Share | -1.75 | -35.23 | -0.62 | -18.61 | -16.31 | |
| Levered Free Cash Flow | -11 | -10.3 | -25.48 | -16.79 | -14.85 | |
| Unlevered Free Cash Flow | -11 | -10.3 | -25.48 | -16.79 | -14.85 | |
| Change in Working Capital | -6.94 | 0.71 | -2.74 | 6.27 | 1.42 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.